NovoLog (insulin aspart) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 85 Diseases   38 Trials   38 Trials   1659 News 


«12...234567891011121314»
  • ||||||||||  ultra-rapid acting insulin (AT247) / Arecor
    Trial completion:  AT247, NovoRapid (clinicaltrials.gov) -  Sep 29, 2019   
    P1,  N=18, Completed, 
    Recruiting --> Completed
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion, Trial primary completion date:  Evaluation of Fiasp (clinicaltrials.gov) -  Sep 19, 2019   
    P4,  N=20, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Nov 2018 --> Mar 2019
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Review, Journal:  Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. (Pubmed Central) -  Sep 6, 2019   
    Furthermore, administration of faster aspart up to 20 min after the start of a meal permitted similar glucose control to aspart given preprandially. These data, taken in totality, illustrate the potential role of faster insulin aspart in clinical practice.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
    Enrollment change:  The Insulin-Only Bionic Pancreas Bridging Study (clinicaltrials.gov) -  Sep 4, 2019   
    P2/3,  N=36, Completed, 
    These data, taken in totality, illustrate the potential role of faster insulin aspart in clinical practice. N=56 --> 36
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  SNIFF-Quick: Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (clinicaltrials.gov) -  Sep 3, 2019   
    P1,  N=24, Completed, 
    N=56 --> 36 Recruiting --> Completed | Trial completion date: Sep 2019 --> Apr 2019 | Trial primary completion date: Sep 2019 --> Apr 2019
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them? (Pubmed Central) -  Aug 28, 2019   
    Unexplained hyperglycemia and premature infusion set changes were more common with FIASP than with insulin aspart. This study demonstrated sufficient safety and efficacy of FIASP in the pump setting to pave the way for longer, larger and more definitive clinical trials.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk
    Trial completion date, Trial primary completion date, Surgery:  Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes (clinicaltrials.gov) -  Aug 26, 2019   
    P4,  N=180, Recruiting, 
    This study demonstrated sufficient safety and efficacy of FIASP in the pump setting to pave the way for longer, larger and more definitive clinical trials. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Dec 2020
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia (clinicaltrials.gov) -  Aug 26, 2019   
    P4,  N=3, Terminated, 
    Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Dec 2020 N=50 --> 3 | Trial completion date: Dec 2020 --> Aug 2019 | Recruiting --> Terminated | Trial primary completion date: Mar 2020 --> Aug 2019; Unable to recruit sufficient number of patients
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Rapid-acting insulin in type 1 diabetes: Regular insulin, rapid analogues or faster analogues? (Auditorium) -  Aug 15, 2019 - Abstract #IDF2019IDF_262;    
    Three first-generation rapid acting types are currently available (aspart, glulisine, lispro)...The faster profile is mediated through niacinamide which accelerates the initial insulin aspart absorption, but the mechanism of action appears to be multifaceted...All patients with type 1 diabetes should have rapid-acting or regular insulin available for crisis management. Learning objectivesKnow about differences in insulin action between regular insulin, rapid analogues or faster analoguesUnderstand the indications regular insulin, rapid analogues or faster analoguesGain knowledge in practical aspects using prandial/bolous insulin in different clinical situations
  • ||||||||||  SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi, Lantus (insulin glargine) / Sanofi
    Trial completion date, Trial primary completion date:  GEMELLI X: Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (clinicaltrials.gov) -  Aug 8, 2019   
    P3,  N=184, Recruiting, 
    Learning objectivesKnow about differences in insulin action between regular insulin, rapid analogues or faster analoguesUnderstand the indications regular insulin, rapid analogues or faster analoguesGain knowledge in practical aspects using prandial/bolous insulin in different clinical situations Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Insulins for type 2 diabetes. (Pubmed Central) -  Aug 6, 2019   
    Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020 No abstract available
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Clinical, Journal:  Impact of a Basal-Bolus Insulin Regimen on Metabolic Control and Risk of Hypoglycemia in Patients With Diabetes Undergoing Peritoneal Dialysis. (Pubmed Central) -  Jul 28, 2019   
    Over 6 weeks of treatment, no microscopically confirmed infusion-set occlusions were observed for faster aspart or insulin aspart, indicating similar compatibility with CSII use. An intervention consisting of an educational program and a basal-bolus insulin regimen in type 1 and type 2 diabetes mellitus patients undergoing PD caused a decrease in HbA1c levels, and mean blood glucose levels as measured from CGM with no significant increases in hypoglycemia episodes.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk, Novolog Mix 70/30 (insulin aspart protamine and insulin aspart injectable suspension) / Novo Nordisk
    Clinical, Journal:  Nondestructive Quantitative Inspection of Drug Products Using Benchtop NMR Relaxometry-the Case of NovoMix® 30. (Pubmed Central) -  Jul 11, 2019   
    The water proton transverse relaxation rate was found to be sensitive to detecting concentration changes of the FlexPen® product. These findings support the development of vial-level verification-based quality control for drug products where every vial in a batch is inspected quantitatively but nondestructively.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Preclinical, Journal:  Delayed insulin absorption correlates with alterations in subcutaneous depot kinetics in rats with diet-induced obesity. (Pubmed Central) -  Jul 6, 2019   
    ...Injection depots were visualized with micro X-ray computed tomography imaging upon s.c. administration of insulin aspart mixed with the contrast agent iomeprol, and insulin aspart exposure was measured by means of luminescent oxygen channelling immunoassay...Depot disappearance from the s.c. tissue was inversely correlated with body fat mass (p < 0.05). Alterations in s.c. injection depot structure and kinetics may play a role in the obesity-associated delay in insulin absorption.
  • ||||||||||  Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date, Metastases:  Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) (clinicaltrials.gov) -  Jul 5, 2019   
    P=N/A,  N=176, Suspended, 
    Alterations in s.c. injection depot structure and kinetics may play a role in the obesity-associated delay in insulin absorption. Trial completion date: Aug 2019 --> Dec 2020 | Trial primary completion date: Jul 2016 --> Dec 2020
  • ||||||||||  Kixelle (insulin aspart biosimilar) / Viatris, Biocon
    Enrollment closed:  Mylan Insulin Aspart Study (clinicaltrials.gov) -  Jun 27, 2019   
    P3,  N=500, Active, not recruiting, 
    Trial completion date: Aug 2019 --> Dec 2020 | Trial primary completion date: Jul 2016 --> Dec 2020 Recruiting --> Active, not recruiting
  • ||||||||||  Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Identification of N-Terminally Truncated Derivatives of Insulin Analogs Formed in Pharmaceutical Formulations. (Pubmed Central) -  Jun 24, 2019   
    We believe this to be the first published case of a therapeutic approach to the treatment of hyperinsulinemic hypoglycemia associated with insulin antibodies that factors in blood pH and the correction of acidosis using sodium bicarbonate, which physicians could consider. The following derivatives formed by truncation of the B chain in insulin analogs were identified in pharmaceutical formulations: desPhe-N-formyl-Val derivative, desPhe derivative, pyroGlu derivative.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Octreotide for the treatment of intentional insulin aspart overdose in a non-diabetic patient. (Pubmed Central) -  Jun 22, 2019   
    Octreotide, a somatostatin analogue, may help prevent dextrose-induced hypoglycemia and improve the management in select insulin overdose patients; large infusion volumes resulted in significant peripheral edema. Treatment with octreotide was initiated 12.5 hours post-injection and was followed by a stabilization of blood glucose concentration in this non-diabetic patient.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
    Clinical, Journal:  Effects of acarbose and siglitine on blood glucose fluctuation and islet β-cell function in patients with type 2 diabetes mellitus. (Pubmed Central) -  Jun 22, 2019   
    The HOMA-IR (CP) index of groups B and C was significantly lower than that of group A (P less than 0.01), and there was no statistically significant difference between groups B and C (P less than 0.05). Sitagliptin combined with intensive insulin pump therapy can reduce blood glucose fluctuation throughout the day, reduce insulin dosage, improve islet B cell function and reduce hypoglycemia better than intensive insulin pump therapy alone.